Cencora, Inc. (VIE:ABC)
Austria · Delayed Price · Currency is EUR | Market Cap | 51.21B +6.6% |
| Revenue (ttm) | 277.46B +7.4% |
| Net Income | 1.38B +16.4% |
| EPS | 7.10 +18.6% |
| Shares Out | n/a |
| PE Ratio | 37.00 |
| Forward PE | 17.17 |
| Dividend | 1.98 (0.76%) |
| Ex-Dividend Date | Feb 13, 2026 |
| Volume | n/a |
| Average Volume | 0 |
| Open | 262.20 |
| Previous Close | 259.80 |
| Day's Range | 262.10 - 262.20 |
| 52-Week Range | 237.50 - 330.40 |
| Beta | n/a |
| RSI | 29.84 |
| Earnings Date | May 6, 2026 |
About Cencora
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company’s U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, ... [Read more]
Financial Performance
In fiscal year 2025, Cencora's revenue was $321.33 billion, an increase of 9.31% compared to the previous year's $293.96 billion. Earnings were $1.55 billion, an increase of 2.99%.
Financial numbers in USD Financial StatementsNews
CareMetx Acquires U.S.-based Patient Services and Free Goods Pharmacy Operations from Cencora, Significantly Expanding Its Patient Access Platform
As demand for technology-forward patient services accelerates, combined organization positions CareMetx to deliver greater innovation for biopharma clients. As demand for technology-forward patient se...
Cencora Announces Date and Time for Second Quarter Fiscal 2026 Earnings Release
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2026 on Wednesday, May 6, 2026, prior to the opening...
Cencora to buy retina business of EyeSouth Partners for $1.1 billion
Drug distributor Cencora said on Monday it would buy the retina business of eye care network EyeSouth Partners for $1.1 billion, expanding its eye care unit.
Cencora to Expand Retina Consultants of America Through Acquisition of EyeSouth Partners' Retina Business
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced the signing of a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. Upon completion of t...
Cencora Announces Financial Leadership Transition
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that James F. Cleary will retire as Executive Vice President and Chief Financial Officer effective June 30, 2026. Cencora ...
Cencora Transcript: Leerink Global Healthcare Conference 2026
Strong U.S. segment growth and expanded MSO capabilities drove increased guidance, while strategic acquisitions and divestitures enhanced operational focus. Specialty and generics markets remain healthy, with ongoing investments in synergies, contracting, and customer relationships supporting long-term growth.
Cencora Transcript: Barclays 28th Annual Global Healthcare Conference
Strong U.S. segment growth and raised guidance followed the OneOncology acquisition, with ongoing MSO strategy execution and a robust pipeline of generics and biosimilars supporting long-term growth. Capital deployment is focused on de-leveraging, with future M&A limited to bolt-on specialty investments.
Cencora Transcript: AGM 2026
The meeting covered director elections, executive compensation, and auditor ratification, all of which passed by majority vote. Financial results showed 16% growth in adjusted operating income and EPS, with new acquisitions and a $1 billion investment commitment announced.
Cencora's animal health unit to merge with Covetrus in $3.5 billion deal
Drug distributor Cencora will merge its MWI Animal Health unit with privately held Covetrus in a deal that values MWI at $3.5 billion, the companies said on Wednesday.
Covetrus and MWI Animal Health to Merge
CONSHOHOCKEN, Pa. & PORTLAND, Maine--(BUSINESS WIRE)--Cencora (NYSE: COR) and Covetrus, a global animal health technology and services company, today announced that they have entered into a definitive...
Cencora Closes $3.0 Billion Senior Notes Offering
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced the closing of its public offering of $500 million aggregate principal amount of its 3.950% Senior Notes due February 13, ...
Cencora Prices $500 Million 3.950% Senior Notes Due 2029, $500 Million 4.250% Senior Notes Due 2030, $500 Million 4.600% Senior Notes Due 2033, $1.0 Billion 4.900% Senior Notes Due 2036 and $500 Million 5.650% Senior Notes Due 2056
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it priced $500 million aggregate principal amount of its 3.950% Senior Notes due February 13, 2029 (the “2029 Notes”)...
Cencora Earnings Call Transcript: Q1 2026
Delivered strong Q1 FY26 results with 12% adjusted operating income growth and 9% EPS growth, completed OneOncology acquisition, and raised full-year guidance for revenue and operating income. U.S. Healthcare Solutions led performance, with MSO expansion and specialty focus driving growth.
Cencora beats quarterly profit estimates on strong demand for specialty medicines
Cencora on Wednesday beat Wall Street estimates for first-quarter profit, as the drug distributor rode the wave of sustained demand for specialty medicines and GLP-1 therapies.
Cencora Reports Fiscal 2026 First Quarter Results
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2026 first quarter ended December 31, 2025, revenue increased 5.5 percent year-over-year to $85.9 billion...
Curant Rare Announces Collaboration with Cencora to Support Commercialization of Rare and Orphan Drug Products
ATLANTA--(BUSINESS WIRE)--Curant Rare today announced a strategic collaboration with Cencora, a global pharmaceutical solutions organization, that aims to provide pharmaceutical companies developing r...
Cencora Elects Ellen Cooper to Its Board of Directors
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Ellen Cooper as a new independent director, effective January 20, 2026. Ms. Cooper...
Cencora Transcript: 44th Annual J.P. Morgan Healthcare Conference
Strong revenue and profit growth driven by specialty pharmaceuticals, MSO expansion, and strategic investments. Raised long-term guidance following acquisitions and continued focus on digital transformation, productivity, and global logistics. Regulatory and market trends remain manageable.
Cencora Announces Date and Time for First Quarter Fiscal 2026 Earnings Release
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the First Quarter of Fiscal 2026 on Wednesday, February 4, 2026, prior to the ope...
Cencora to take majority control of OneOncology to expand cancer services
U.S. drug distributor Cencora said on Monday it will take majority control of cancer care network OneOncology in a deal that values the business at $7.4 billion, as it moves to expand services for com...
Cencora Accelerates OneOncology Acquisition, Extending Solutions Offering for Community Oncology
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced it has entered into a definitive agreement to acquire the majority of the outstanding equity interests that it does not cu...
Cencora Enhances Global Pharmaceutical Logistics Services, Cold Chain Capabilities
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global pharmaceutical solutions company, today announced investments to enhance its third-party logistics (3PL) capabilities in the United States and Eur...
Cencora Transcript: Citi Annual Global Healthcare Conference 2025
Strong fiscal 2025 results and raised long-term guidance reflect robust specialty and MSO growth, with continued investment in innovation and capital deployment. International operations are being streamlined, and key client relationships remain stable. Biosimilars and GLP-1s offer margin opportunities, while capital is balanced across investments, acquisitions, and shareholder returns.
Cencora Transcript: Evercore ISI 8th Annual HealthCONx Conference
Strong specialty market growth, MSO expansion, and strategic capital deployment are driving robust operating income and long-term guidance. Full ownership of OneOncology and digital transformation are expected to enhance synergies and efficiency, while regulatory advocacy and evolving market trends support continued outperformance.
Cencora Earnings Call Transcript: Q4 2025
Strong fiscal 2025 results featured 16% adjusted operating income and EPS growth, driven by specialty focus and strategic investments. Long-term guidance was raised, with continued infrastructure expansion and portfolio optimization, despite headwinds from a major customer loss and PharmaLex impairment.